15.02.2024 Epigenomics AG  DE000A37FT41

EQS-News: Epigenomics AG: Jochen Hummel appointed to the Supervisory Board to replace Heikki Lanckriet


 

EQS-News: Epigenomics AG / Key word(s): Personnel
Epigenomics AG: Jochen Hummel appointed to the Supervisory Board to replace Heikki Lanckriet

15.02.2024 / 10:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


Epigenomics AG: Jochen Hummel appointed to the Supervisory Board to replace Heikki Lanckriet

Berlin, February 15, 2024 - Epigenomics AG (Frankfurt General Standard: ECX; the “Company”), a holding company focusing on investments in the field of minimally invasive blood tests for cancer detection, announces that upon application of the Executive Board and the Supervisory Board, the Charlottenburg District Court has appointed Mr. Jochen Hummel as a member of the Company's Supervisory Board effective February 5, 2024. Mr. Hummel replaces Dr. Heikki Lanckriet, who stepped down from the Board on January 31, 2024. For the time being, Mr. Hummel's appointment will end with the Annual General Meeting of Epigenomics AG, which is scheduled to take place on May 29, 2024.

Jochen Hummel has been a partner at WSB Wolf Beckerbauer Hummel & Partner, Steuerberatungsgesellschaft mbB since 2011. As a tax advisor and specialist consultant for international tax law, he is an expert in the field of corporate transactions, international tax law and group structures.

Dr. Helge Lubenow, Chairwoman of the Supervisory Board: “We are very much looking forward to working with Mr. Hummel and his extensive expertise, which will enrich our Board.”

 

Contact:
Company
Epigenomics AG, Bertha-Benz-Strasse 5, 10557 Berlin
Tel +49 (0) 30 24345 0, Fax +49 (0) 30 24345 555, Email: [email protected]

Investor Relations
IR.on AG, Frederic Hilke, Tel +49 221 9140 970, Email: [email protected]

 

Note on forward-looking statements

This publication expressly or implicitly contains forward-looking statements concerning Epigenomics AG and its business. These statements involve certain known and unknown risks, uncertainties and other factors that may cause Epigenomics AG's actual results, financial condition and performance to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics makes this announcement as of the date of this release and does not intend to update any forward-looking statements contained herein as a result of new information or future events or otherwise.

 



15.02.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Epigenomics AG
Bertha-Benz-Straße 5
10557 Berlin
Germany
Phone: +49 30 24345-0
Fax: +49 30 24345-555
E-mail: [email protected]
Internet: www.epigenomics.com
ISIN: DE000A37FT41
WKN: A37FT4
Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1838167

 
End of News EQS News Service

1838167  15.02.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1838167&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 1,15 1,53 1,13 0,84 6,20 0,49 0,34
EBITDA1,2 -9,95 -12,78 -14,16 -11,09 -1,94 -11,30 -2,91
EBITDA-Marge3 -865,22 -835,29 -1.253,10 -1.320,24 -31,29 -2.306,12
EBIT1,4 -10,29 -12,90 -14,67 -11,63 -2,35 -12,05 -4,50
EBIT-Marge5 -894,78 -843,14 -1.298,23 -1.384,52 -37,90 -2.459,18 -1.323,53
Jahresüberschuss1 -10,24 -12,69 -17,02 -11,69 -2,43 -12,02 -4,46
Netto-Marge6 -890,43 -829,41 -1.506,19 -1.391,67 -39,19 -2.453,06 -1.311,77
Cashflow1,7 -9,58 -10,35 -13,51 -9,57 -4,15 -12,02 -5,71
Ergebnis je Aktie8 -70,40 -75,20 -73,00 -40,40 -4,40 -14,80 -5,15
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Baker Tilly

INVESTOR-INFORMATIONEN
©boersengefluester.de
Epigenomics
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A37FT4 1,700 1,49
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 0,00 0,00 -0,03
KBV KCV KUV EV/EBITDA
-0,19 - 4,39 -3,87
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,00 0,00 0,00 29.05.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
30.09.2024 14.03.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-1,56% 169,84% -10,05% -68,13%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Epigenomics AG  ISIN: DE000A37FT41 können Sie bei EQS abrufen


Biotechnologie , A37FT4 , ECX , XETR:ECX